• DCR . • PROs of pancreatic cancer symptoms. • Incidence of treatment- emergent AEs, SAEs , graded using the NCI CTCAE Version 4.03. Exploratory Endpoints: • Determination of tumor genomic, transcriptomic, and proteomic profiles and correlations with subject outcomes. • Determination of PD-L1 expression from ct RNA and correlation with subject outcomes. Confidential and Proprietary 8 NANT Pancreatic Cancer Vaccine NantCell, Inc. Clinical Trial Protocol: QUILT -3.039 Amendment 2 Enrollment (planned): In the phase 1b portion of the study, 6 to 24 subjects will be enrolled . The initial 3 subjects will be enrolled in a staggered fashion, with a 21- day interval between each subject. In the phase 2 portion of the study, 23 subjects will be enrolled in the first stage of Simon’s two- stage optimal design. If the study proceeds to the second stage of Simon’s two -stage optimal design, an additional 33 subjects will be enrolled in the sec ond stage, for a total of 56 subjects in the phase 2 portion of the study. The maximum total enrollment will the study is 80 subjects. Diagnosis and Main Criteria for Inclusion: Inclusion Criteria: 1. Age ≥ 18 years old.